Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

Vaccine

Volumn 29, Issue 5, 2011, Pages 1072-1081

  Brunelli, Brunella ^a   Del Tordello, Elena ^a   Palumbo, Emmanuelle ^a   Biolchi, Alessia ^a   Bambini, Stefania ^a   Comanducci, Maurizio ^a   Muzzi, Alessandro ^a   Pizza, Mariagrazia ^a   Rappuoli, Rino ^a   Donnelly, John J ^a   Giuliani, Marzia M ^a   Serruto, Davide ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

FHbp; Isogenic strains; Neisseria meningitidis; Serum bactericidal activity; Vaccine

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; DRUG SENSITIVITY; HUMAN; HUMAN EXPERIMENT; IMMUNITY; INFANT; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; IMMUNE SERA; INFANT; MENINGOCOCCAL VACCINES; MICE; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS; POLYMORPHISM, GENETIC;

EID: 78751574263     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.064     Document Type: Article

References (41)

1. Stephens D.S. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009, 27(June (Suppl. 2)):B71-B77.
2. Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev Vaccines 2009, 8(May (5)):529-542.
3. Sharip A., Sorvillo F., Redelings M.D., Mascola L., Wise M., Nguyen D.M. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 2006, 25(March (3)):191-194.
4. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 31(January (1)):27-36.
5. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(August (8346)):355-357.
6. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(June (Suppl. 2)):B3-12.
7. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362(April (16)):1511-1520.
8. Feavers I.M., Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009, 27(June (Suppl. 2)):B42-50.
9. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(March (5459)):1816-1820.
10. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55(February (3)):687-698.
11. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195(June (11)):1445-1454.
12. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010, 107(February (8)):3770-3775.
13. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(March (6)):789-799.
14. Seib K.L., Serruto D., Oriente F., Delany I., Adu-Bobie J., Veggi D., et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009, 77(January (1)):292-299.
15. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(July (29)):10834-10839.
16. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(March (17-18)):2191-2196.
17. Wedege E., Bolstad K., Aase A., Herstad T.K., McCallum L., Rosenqvist E., et al. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 2007 Jul, 14(7):830-838.
18. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(April (4)):2088-2100.
19. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(July (37)):6086-6093.
20. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(June (Suppl. 2)):B112-B116.
21. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(June (24)):5093-5107.
22. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(July (1)):501-510.
23. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004, 32(5):1792-1797.
24. Jones D.T., Taylor W.R., Thornton J.M. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 1992, 8(June (3)):275-282.
25. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4(July (4)):406-425.
26. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(August (8)):1596-1599.
27. Ieva R., Alaimo C., Delany I., Spohn G., Rappuoli R., Scarlato V. CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription. J Bacteriol 2005, 187(May (10)):3421-3430.
28. Granoff D.M, Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998, 160(May (10)):5028-5036.
29. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005, 12(August (8)):970-976.
30. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, (May).
31. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27(May (21)):2794-2803.
32. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009, 27(March (10)):1579-1584.
33. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterisation of fHbp, nhba (gna2132), nadA, porA and Sequence Type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17(April (6)):919-929.
34. Findlow J., Holland A., Andrews N., Weynants V., Sotolongo F., Balmer P., et al. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay. Clin Vaccine Immunol 2007, 14(November (11)):1451-1457.
35. Oriente F., Scarlato V., Delany I. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol 2010, 192(February (3)):691-701.
36. Moe G.R., Zuno-Mitchell P., Lee S.S., Lucas A.H., Granoff D.M. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infection and immunity 2001, 69(June (6)):3762-3771.
37. Moe G.R., Tan S., Granoff D.M. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999, 67(November (11)):5664-5675.
38. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994, 62(October (10)):4419-4424.
39. Kortekaas J., Pettersson A., van der Biezen J., Weynants V.E., van der Ley P., Poolman J., et al. Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine 2007, 25(January (1)):72-84.
40. Dull P., Kimura A., Vienken K., Ypma E., Kleisnschmidt A., De Tora L., et al. Phase III formulation development of recombinant meningococcal B vaccine (rMenB) containing fHbp, NHBA, NadA, and New Zealand strain (NZ98/254) outer membrane vesicles (OMV). 28th ESPID Meeting 2010, [Nice; 2010].
41. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, (October).